Effect of puta in Abharaka marana w.s.r. to Madhumeha ( Type 2 DM)

Phase 1/2

Not yet recruiting

• Conditions: MADHUMEHA (TYPE-2 DM)

• Registration Number: CTRI/2015/10/006281
• Lead Sponsor: Institute for Post Graduate Teaching and Research in Ayurveda

Brief Summary

Almost all *Rasavarga* *Dravya* are used therapeutically essentially after *Shodhana* and *Marana*. *Abhraka* is one among the drugs which are said to use after proper process of *Marana.**Abhraka* is among *Rasavarga* *dravya* for whome maximum number of repetitive cycles of *Puta* that is 1000 are mentioned in ancient classics on *Rasa Shastra*. Although *Bhasma* of *Abhraka* can be prepared with single *Puta,* yet 1000 repetitive cycles of *Puta* are also mentioned for its *marana*.

*Abhraka* is said to posses *Pramehahara*  property and said to be used in all diseases. It is among few *Rasavarga* *dravya* which predominantly have *Yogavahi* and *Rasayana* property.In Prameha, 10 dushya gets affected hence drug posseing *Rasayana* property along with *Pramehahara* effect would be drug of choice, which Abhraka Bhasma.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2015-04-07
• Study Start: 2015-08-17

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Both the sexes having Age between 30 years to 60 years Patients having classical symptomatology of Madhumeha (Prabhutamutrata, Avilamutrata etc) Symptoms of Diabetes (Polyuria, Polydipsia, Polyphagia and Weight loss) Patients having Blood sugar Fasting Blood Sugar ≥ 126 mg/dl Post Prandial Blood Sugar ≥ 200 mg/dl.

Exclusion Criteria

• Age below 30 and above 60 years.
• Patients of Diabetes Mellitus receiving Insulin.
• Malignant and accelerated Hypertension.
• Patients having chronic complications of Diabetes Mellitus a.Microvascular: Retinopathy, Neuropathy, & Nephropathy.
• b.Macrovascular: Coronary artery disease, Peripheral vascular disease & Cerebro-vascular disease.
• c.Other chronic debilitating diseases like STD etc.
• 5.Pregnant women.
• 6.Lactating mothers.
• 7.Secondary Diabetes mellitus.
• 8.Patients of any other severe illness.
• 9.Severe Iron deficiency anemia with Hb% less than 7mg/dl.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
It is expected that the trial drugs will exert a significant action over classical symptomatology of Madhumeha (Prabhutamutrata, Avilamutrata)	up to 8 weeks

Secondary Outcome Measures

Name	Time	Method
It will help to live diabetic patient more healthy and without complications	Up to 4 weeks

Trial Locations

Locations (1)

IPGT and RA; 🇮🇳 Jamnagar, GUJARAT, India

IPGT and RA

🇮🇳Jamnagar, GUJARAT, India

SUNIL BHURKUNDE

Principal investigator

8484013788

sunilmdjamnagar@gmail.com